Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human umbilical cord blood preparation is a biologic therapy derived from umbilical cord blood, which is rich in hematopoietic stem cells, mesenchymal stem cells, and various regenerative growth factors. In the field of reproductive medicine, it is being investigated for its potential to restore ovarian function in women with premature ovarian insufficiency (POI). The preparation is hypothesized to improve the ovarian microenvironment, stimulate the activation of dormant follicles, and modulate reproductive hormone levels. Clinical research conducted by the Clinic of Professor Feskov has utilized these preparations in conjunction with human placenta fragments to enhance outcomes in in vitro fertilization (IVF) programs, specifically aiming to increase antral follicle counts and the number of mature oocytes retrieved.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human umbilical cord blood preparation.